- Home
- DQ vs EWTX Comparison
DQ vs EWTX Comparison
Compare DQ & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- EWTX
- Stock Information
- Founded
- DQ 2006
- EWTX 2017
- Country
- DQ China
- EWTX United States
- Employees
- DQ N/A
- EWTX N/A
- Industry
- DQ Semiconductors
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- EWTX Health Care
- Exchange
- DQ Nasdaq
- EWTX Nasdaq
- Market Cap
- DQ 1.4B
- EWTX 1.2B
- IPO Year
- DQ 2010
- EWTX 2021
- Fundamental
- Price
- DQ $13.36
- EWTX $14.28
- Analyst Decision
- DQ Hold
- EWTX Buy
- Analyst Count
- DQ 6
- EWTX 8
- Target Price
- DQ $20.31
- EWTX $40.13
- AVG Volume (30 Days)
- DQ 694.1K
- EWTX 1.1M
- Earning Date
- DQ 04-29-2025
- EWTX 05-08-2025
- Dividend Yield
- DQ N/A
- EWTX N/A
- EPS Growth
- DQ N/A
- EWTX N/A
- EPS
- DQ N/A
- EWTX N/A
- Revenue
- DQ $737,683,000.00
- EWTX N/A
- Revenue This Year
- DQ N/A
- EWTX N/A
- Revenue Next Year
- DQ $90.46
- EWTX N/A
- P/E Ratio
- DQ N/A
- EWTX N/A
- Revenue Growth
- DQ N/A
- EWTX N/A
- 52 Week Low
- DQ $12.41
- EWTX $10.60
- 52 Week High
- DQ $30.85
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- DQ 41.53
- EWTX 43.22
- Support Level
- DQ $13.51
- EWTX $13.80
- Resistance Level
- DQ $14.11
- EWTX $14.68
- Average True Range (ATR)
- DQ 0.61
- EWTX 0.78
- MACD
- DQ 0.04
- EWTX 0.08
- Stochastic Oscillator
- DQ 4.56
- EWTX 29.68
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.